CymaBay price target raised to $18 from $15 at BTIG
The Fly

CymaBay price target raised to $18 from $15 at BTIG

BTIG analyst Julian Harrison raised the firm’s price target on CymaBay Therapeutics to $18 from $15 and keeps a Buy rating on the shares. The ELATIVE trial results from Ipsen and Genfit leave a good chance for CymaBay’s seladelpar to emerge as the best-in-class PPAR agonist for primary biliary cholangitis, the analyst tells investors in a research note. The firm views the results as the “best case scenario” for CymaBay.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on CBAY:

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App